Asset profile
BEBT-908
Small molecule
Evidence outlook · lead readout
NCT06082596 · Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06082596: This was an open-label, single-arm dose-escalation study with no randomization, no blinding, and no control arm, designed purely to establish a tolerable dose; any efficacy signal was only a secondary, exploratory measure, and results have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.